0001104659-23-113576.txt : 20231102 0001104659-23-113576.hdr.sgml : 20231102 20231102070526 ACCESSION NUMBER: 0001104659-23-113576 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231102 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 231370023 BUSINESS ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 8-K 1 tm2329595d1_8k.htm FORM 8-K
false 0001761612 00-0000000 true 0001761612 2023-11-02 2023-11-02 0001761612 us-gaap:CommonStockMember 2023-11-02 2023-11-02 0001761612 bcyc:AmericanDepositarySharesMember 2023-11-02 2023-11-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

November 2, 2023

Date of Report (Date of earliest event reported)

 

Bicycle Therapeutics plc

(Exact name of registrant as specified in its charter)

 

England and Wales   001-38916   Not applicable

(State or other jurisdiction
of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

Blocks A & B, Portway Building,
Granta Park Great Abington, Cambridge
United Kingdom

CB21 6GS
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: +44 1223 261503

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Ordinary shares, nominal value £0.01 per share n/a The Nasdaq Stock Market LLC*
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC The Nasdaq Stock Market LLC

 

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 2.02. Results of Operations and Financial Condition

 

On November 2, 2023, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter ended September 30, 2023 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d)       Exhibits

 

Exhibit No.   Description
99.1   Press Release issued November 2, 2023
104   Cover Page Interactive Data File (formatted in Inline XBRL)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 2, 2023 BICYCLE THERAPEUTICS PLC
   
   
  By: /s/ Alethia Young
  Name: Alethia Young
  Title: Chief Financial Officer

 

 

 

 EX-99.1 2 tm2329595d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day

 

R&D Day on December 14 to provide clinical updates for BT8009, BT5528 and BT7480, and highlight broad capabilities of novel Bicycle® technology

 

Alignment with FDA on expedited development and design of Phase 2/3 registrational trial for BT8009 in metastatic bladder cancer, to be initiated in 1Q 2024

 

Selection of BT8009 for new FDA Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) Program to facilitate expedited CMC development and commercial manufacturing readiness

 

Cash and cash equivalents of $572.1 million as of September 30, 2023, including approximately $215.1 million in net proceeds from July 2023 public offering 

  

CAMBRIDGE, England & BOSTON, November 2, 2023 – Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates. 

 

“In the third quarter, we took important steps toward achieving our goal of quickly getting our novel therapies to those who need them. We are extremely pleased to have aligned with the FDA on an expedited clinical development plan and regulatory pathway for BT8009, our lead investigational therapy for metastatic bladder cancer, and that the agency selected BT8009 to be part of a new program that will help facilitate its expedited CMC development. Through close collaboration with the FDA, we will work to ensure BT8009’s commercial manufacturing readiness keeps pace with its expedited clinical development timeframe,” said Kevin Lee, Ph.D., CEO of Bicycle Therapeutics. “With a strengthened balance sheet through the proceeds of an upsized equity offering completed in July, we believe we are well-positioned to conduct our Phase 2/3 registrational trial, scheduled to begin in the first quarter of 2024, to support the potential accelerated approval of BT8009 in a broad metastatic bladder cancer population. Additionally, we continue to advance our research and development efforts across our pipeline, and we look forward to providing clinical updates on BT8009, BT5528 and BT7480 at our R&D Day next month.”

 

Third Quarter 2023 and Recent Highlights 

 

●BT8009 Selected to Participate in U.S. Food and Drug Administration (FDA) Program to Expedite Commercial Manufacturing Readiness. In October, Bicycle Therapeutics announced the FDA selected BT8009 to participate in the new Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) Program, which was created to facilitate CMC development for therapies with expedited clinical development timeframes, based on the anticipated clinical benefits of earlier patient access to the therapy. BT8009 is one of up to nine products selected for the inaugural cohort of the CDRP Program.

 

 

 

 

 

●Announced Expedited Clinical Development Plan and Regulatory Pathway for BT8009 in Metastatic (Urothelial) Bladder Cancer. In September, Bicycle Therapeutics announced the company will proceed with its plan to expedite development of BT8009 for metastatic bladder cancer following recent discussions with the FDA. The company aligned with the FDA on a Phase 2/3 registrational trial, called Duravelo-2, that has an innovative design allowing for potential accelerated approval in untreated (first-line) and previously treated (second-line plus) metastatic bladder cancer. The company plans to initiate the Duravelo-2 trial in the first quarter of 2024.

 

oIn Cohort 1, two doses of BT8009 plus standard pembrolizumab regimen will be initially assessed. Following selection of the optimal dose, BT8009 plus pembrolizumab will be evaluated against chemotherapy. Potential accelerated approval will be determined by objective response rate (ORR), and progression-free survival (PFS) will be used to confirm clinical benefit.
oIn Cohort 2, two doses of BT8009 as monotherapy will be initially studied. Following selection of the optimal dose, an additional arm of BT8009 plus standard pembrolizumab regimen will be added. Potential accelerated approval for BT8009 monotherapy and in combination with pembrolizumab will be determined by ORR compared to historical control data. Discussions with the FDA about the design of the confirmatory trial for previously treated metastatic bladder cancer are ongoing.

 

●Raised Net Proceeds of $215.1 Million in Public Offering. In July, Bicycle Therapeutics announced the closing of an underwritten public offering resulting in gross proceeds of approximately $230.0 million, including the full exercise of the underwriters’ option to purchase additional shares. Net proceeds were approximately $215.1 million. In addition, the company also received net proceeds from Bicycle’s at-the-market (ATM) offering program during the third quarter of 2023 totaling $19.4 million.

 

Pipeline updates planned at upcoming Research & Development (R&D) Day on December 14, 2023, in New York

 

Bicycle Therapeutics will provide updates from the company’s Phase 1/2 clinical trials for BT8009, a Bicycle Toxin Conjugate (BTC™) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137. The company will also provide an overview of its novel Bicycle® technology, the broad capabilities of its drug discovery platform and potential future pipeline programs.

 

The R&D Day will begin at 8 a.m. ET on Thursday, December 14, 2023, and will conclude at approximately 12 p.m. ET. Analysts and investors who are interested in attending in person can RSVP to bicycle@argotpartners.com. A webcast of the event will be accessible from the Investor section of the company’s website, www.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event.

 

Financial Results 

 

●Cash and cash equivalents were $572.1 million as of September 30, 2023, compared to $339.2 million as of December 31, 2022. The increase in cash and cash equivalents is primarily due to $215.1 million in net proceeds from the underwritten public offering in July 2023, $34.2 million of year-to-date net proceeds from our ATM offering program and $95.0 million received from our collaboration agreements with Novartis and Bayer, offset by cash used in operating activities.

 

●R&D expenses were $39.9 million for the three months ended September 30, 2023, compared to $22.8 million for the three months ended September 30, 2022. The increase in expense of $17.1 million was primarily due to increased clinical program expenses for BT8009 development and other discovery and platform-related activities, as well as increased personnel-related expenses, including incremental non-cash share-based compensation expense of $0.7 million.

 

 

 

 

 

●General and administrative expenses were $16.3 million for the three months ended September 30, 2023, compared to $10.0 million for the three months ended September 30, 2022. The increase of $6.3 million for the three months ended September 30, 2023, as compared to the same period in the prior year was primarily due to an increase in professional and consulting fees as well as an increase in personnel-related expenses, including incremental non-cash share-based compensation expense of $1.3 million.

 

●Net loss was $49.9 million, or $(1.26) basic and diluted net loss per share, for the three months ended September 30, 2023, compared to net loss of $28.3 million, or $(0.96) basic and diluted net loss per share, for three months ended September 30, 2022. 

 

About Bicycle Therapeutics 

 

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. The company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC™) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase 1/2 trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase 1/2a clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.

 

 

 

 

 

Forward Looking Statements 

 

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Bicycle’s anticipated advancement of its product candidates, including BT8009, BT5528 and BT7480; the anticipated progression of Bicycle’s clinical trials, including the timing of initiation and design of the Duravelo-2 Phase 2/3 clinical trial and potential accelerated approval of BT8009; anticipated clinical and other benefits of Bicycle Therapeutics’ participation in the CDRP Program, including potential earlier patient access to BT8009; the ability of the company to expedite CMC readiness for BT8009, including ensuring that commercial manufacturing readiness for BT8009 keeps pace with its clinical development; the availability of and timing of announcement of data from clinical trials and regulatory updates for clinical candidates, including the planned R&D Day on December 14, 2023; statements regarding Bicycle’s collaborations with Bayer and Novartis; the discovery, development and potential commercialization of potential radiopharmaceutical or other product candidates using Bicycle’s technology under the strategic collaboration agreements; BT8009’s potential to be a transformative therapy for patients with metastatic bladder cancer; and the therapeutic potential for Bicycles in oncology and other applications. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation, progress and completion of clinical trials and clinical development of Bicycle’s product candidates; the risk that Bicycle may not realize the intended benefits of its technology or strategic collaborations; availability and timing of results from clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials may have unsatisfactory outcomes; challenges or delays in the development and preparation of the commercial manufacturing readiness of BT8009; potential adverse effects arising from the testing or use of Bicycle’s product candidates; and other important factors, any of which could cause Bicycle’s actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 3, 2023, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

 

 

 

 

 

 

Bicycle Therapeutics plc

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(Unaudited)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
Collaboration revenues  $5,352   $3,040   $21,645   $11,278 
Operating expenses:                    
Research and development   39,868    22,752    111,799    56,890 
General and administrative   16,281    10,047    45,557    38,830 
Total operating expenses   56,149    32,799    157,356    95,720 
Loss from operations   (50,797)   (29,759)   (135,711)   (84,442)
Other income (expense):                    
Interest income   3,985    1,991    7,726    3,117 
Interest expense   (814)   (817)   (2,443)   (2,518)
Total other income (expense), net   3,171    1,174    5,283    599 
Net loss before income tax provision   (47,626)   (28,585)   (130,428)   (83,843)
Provision for (benefit from) income taxes   2,272    (238)   1,137    (1,104)
Net loss  $(49,898)  $(28,347)  $(131,565)  $(82,739)
Net loss per share, basic and diluted  $(1.26)  $(0.96)  $(3.95)  $(2.79)
Weighted average ordinary shares outstanding, basic and diluted   39,576,467    29,676,021    33,291,701    29,643,502 

 

 

 

 

 

 

Balance Sheets Data

(In thousands)

(Unaudited)

 

   September 30,   December 31, 
   2023   2022 
Cash and cash equivalents  $572,086   $339,154 
Working capital   533,300    316,041 
Total assets   638,683    410,609 
Total shareholders’ equity   416,022    270,783 

 

Investors: 
Stephanie Yao
SVP, Investor Relations and Corporate Communications
ir@bicycletx.com
857-523-8544

 

Media: 
Sarah Sutton 

Argot Partners 
media@bicycletx.com 

212-600-1902 

 

 

 

 EX-101.SCH 3 bcyc-20231102.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bcyc-20231102_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bcyc-20231102_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] American Depositary Shares [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] American Depositary Shares EX-101.PRE 6 bcyc-20231102_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2329595d1_ex99-1img001.jpg GRAPHIC begin 644 tm2329595d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 02, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 02, 2023
Entity File Number 001-38916
Entity Registrant Name Bicycle Therapeutics plc
Entity Central Index Key 0001761612
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One Blocks A & B, Portway Building
Entity Address, Address Line Two Granta Park Great Abington
Entity Address, City or Town Cambridge
Entity Address, Country GB
Entity Address, Postal Zip Code CB21 6GS
City Area Code +44
Local Phone Number 1223 261503
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Ordinary shares, nominal value £0.01 per share
No Trading Symbol Flag true
Security Exchange Name NASDAQ
American Depositary Shares [Member]  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share
Trading Symbol BCYC
Security Exchange Name NASDAQ
XML 9 tm2329595d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001761612 2023-11-02 2023-11-02 0001761612 us-gaap:CommonStockMember 2023-11-02 2023-11-02 0001761612 bcyc:AmericanDepositarySharesMember 2023-11-02 2023-11-02 iso4217:USD shares iso4217:USD shares false 0001761612 00-0000000 true 8-K 2023-11-02 Bicycle Therapeutics plc X0 001-38916 Blocks A & B, Portway Building Granta Park Great Abington Cambridge GB CB21 6GS +44 1223 261503 false false false false Ordinary shares, nominal value £0.01 per share NASDAQ American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *PX8E<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "L.&)7H6R#%NT K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)VG10^CVLN))07!!\1:2V=U@DX9DI-VW-XV[740?P&-F_GSS M#4RG@]1CQ.\>$S#@5F-." #CTE$+4 UB\3 MPVD>.K@"%AAA=.F[@&8EENJ?V-(!=D[.R:ZI:9KJJ2VYO(. MZ?'E[)N97TB MY37F7\E*.@797)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MK#AB5W3:O4HH!0 1A8 !@ !X;"]W;W)K7QLA>UN7/I>;UNP[E(N#W2 MJ5#PS52;A#NX-;.Z38W@41Z4Q'46!*UZPJ6J==KYLZ'IM'7F8JG$T!";)0DW MRYZ(]>*B1FLO#Q[D;.[\@WJGG?*9& GW6SHT<%??J$0R$1:[![WX1:P;=.SU0AW;_"]9 MK-YM-FLDS*S3R3H8"!*I5O_Y\[HCM@).@QT!;!V0=T1]]4,YY25WO-,V>D&, M?QO4_$7>U#P:X*3RHS)R!KZ5$. MY1.K:F:U-FPM5/%*.>F6Y%K&@MQER:1\MN,:04 /&Z=GM(7PG&QX3O;A>1 S M:9WAT&EW/"GM*5RG)\-E"&T:SX7AJGK##H4^E5'I>-=H?X'"KE5[^D^D-TH M@J)H#UXN2%YK[U4Y&2[9BW7X:-\1^'3)>YZD'TCO@ RU<0N^)+U,QI%4,XR^ ML F*%G6PN'&D.P%DIQ5&77@%Q:O]U]1]?PN'5A1^PVT*+ M_UN9"U=@> T?2P>K73TEE/TX^8F,1)A!F2D?;USIWL!RA,-"S,XYD!X0I6%C M#67TB<>9()ZY\2$X"BA)8<+G+V$M*$R#X37_3I.QX7XI1$;+9 );_5V[M@HA M9S*4J' /AA?^ETXD5\_AG*N9V+D7J1"ZZXXNN[]B3(5Y,+SFPY[6@&4H I4;L%^KZ%&:4DLIJ 4')U F32K0\O5C=-I?E XT<[I)+^<"PZN[U^ M[Z=:NY<;?_:X.3KN_ M02P,$% @ K#AB5Y^@&_"Q @ X@P T !X M;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ M9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD M:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N M0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!I MGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87 M$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%> M* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^ MRPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/- M-;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/ M)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#] M! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q M P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL M0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ K#AB5Y>*NQS M $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/ M:(7->=I3W;+T]!;X"O M.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_ M'B4 M?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQFN1BU MMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1P74& M0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L M.>F.7F=Z_S!YU!Y:YU;*O8=7LN48Y0]02P,$% @ K#AB5R0>FZ*M M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V M\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\ M_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!: M(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( *PX8E=E MD'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E M6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#H MG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4S MM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"* MJX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ M R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L M^T%.6X.^D&PO=&AE;64O M=&AE;64Q+GAM;%!+ 0(4 Q0 ( *PX8E=TVKU** 4 $86 8 M " @0P( !X;"]W;W)K&PO7BKL

JQ"(6,P$ "(" / M " 2\1 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "L M.&)7)!Z;HJT #X 0 &@ @ &/$@ >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "L.&)799!YDAD! #/ P $P M @ %T$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) + #X" "^% ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bicycletherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bcyc-20231102.xsd bcyc-20231102_def.xml bcyc-20231102_lab.xml bcyc-20231102_pre.xml tm2329595d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2329595d1_8k.htm": { "nsprefix": "bcyc", "nsuri": "http://bicycletherapeutics.com/20231102", "dts": { "schema": { "local": [ "bcyc-20231102.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "bcyc-20231102_def.xml" ] }, "labelLink": { "local": [ "bcyc-20231102_lab.xml" ] }, "presentationLink": { "local": [ "bcyc-20231102_pre.xml" ] }, "inline": { "local": [ "tm2329595d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://bicycletherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329595d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329595d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "bcyc_AmericanDepositarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://bicycletherapeutics.com/20231102", "localname": "AmericanDepositarySharesMember", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "American Depositary Shares [Member]", "documentation": "American Depositary Shares" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-23-113576-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-113576-xbrl.zip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end